Clinical Trial Update: A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating nusinersen (ISIS 396443) for later-onset spinal muscular atrophy has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Nusinersen (nusinersen)

Snippet

Sponsor: Biogen | Conditions: Spinal Muscular Atrophy | Phase 3 | Status: COMPLETED | Results posted: 2018-02-22